Dermata Therapeutics Warrant
DRMAW
2 hedge funds and large institutions have $14.5K invested in Dermata Therapeutics Warrant in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.61% less ownership
Funds ownership: 1.32% → 0.71% (-0.61%)
48% less capital invested
Capital invested by funds: $28.1K → $14.5K (-$13.6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$253 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BFM
1
Boothbay Fund Management
New York
| $14.5K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| $20 | +$25 | +1,304 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$253 | -12,671 | Closed |
|
DRMAW Hedge Fund Activity: Q1 2026 in Review
2 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Dermata Therapeutics Warrant (DRMAW) for Q1 2026, worth a combined $14.5K — down 48% from $28.1K a quarter earlier.
Fund positioning in DRMAW was balanced in Q1 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $25. The largest seller was Susquehanna International Group, exiting entirely with an estimated $253 sold.
- 2 institutional investors held Dermata Therapeutics Warrant (DRMAW) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $14.5K of Dermata Therapeutics Warrant stock for Q1 2026, down 48% quarter-over-quarter.
- 1 fund opened new Dermata Therapeutics Warrant positions in Q1 2026 and 1 closed out, a net change of 0 holders.
- The largest Dermata Therapeutics Warrant buyer in Q1 2026 was UBS Group, an estimated $25 added.
- The largest Dermata Therapeutics Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $253 sold.
Based on aggregated 13F filings for Q1 2026.